Minerva Neurosciences, Inc.
Minerva Neurosciences Announces Departure of Directors
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen. Following the Company's recent public offering and the resultant improvement in its financial position, Dr. Ollier and Mr. Vandervelpen will step down to focus on their private equity activities. Their resignations are effective today.
"We would like to thank Michele and Nico for their invaluable contributions to Minerva as a private company and as it has transitioned during the past three years from a venture capital-backed company to a publicly traded company that has advanced several assets into late-stage clinical development," said Marc Beer, chairman of Minerva.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-202 (JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com .
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
VITEC20.3.2018 17:01 | pressemeddelelse
VITEC Adds Powerful New Video Wall and DRM Functionality to EZ TV IPTV and Digital Signage Platform
Millennial Esports Corp.20.3.2018 14:00 | pressemeddelelse
Millennial Esports' Eden Games Amongst First Studios to Integrate Amazon GameOn
Merus N.V.20.3.2018 12:01 | pressemeddelelse
Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer
Auth020.3.2018 10:02 | pressemeddelelse
Auth0 Announces Key Distribution Partnership with AppXite
McDonald's Corporation20.3.2018 09:05 | pressemeddelelse
McDonald's Becomes the First Restaurant Company to Set Approved Science Based Target to Reduce Greenhouse Gas Emissions
Elemica19.3.2018 13:11 | pressemeddelelse
New Elemica Trace Solution Delivers Shipment Risk Analysis for Digital Transformation
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum